Metoclopramide, H 2 Blockers, and Proton Pump Inhibitors: Pharmacotherapy for Gastroesophageal Reflux in Neonates

Clinics in Perinatology

Volumn 39, Issue 1, 2012, Pages 99-109

  Malcolm, William F ^a   Cotten, C Michael ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gastroesophageal reflux; H 2 blocker; Metoclopramide; Neonate; Proton pump inhibitor

Indexed keywords

ALGINIC ACID; CIMETIDINE; CISAPRIDE; CYTOCHROME P450; DOMPERIDONE; DOPAMINE 2 RECEPTOR; ERYTHROMYCIN; ESOMEPRAZOLE; FAMOTIDINE; GAVISCON; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MAGNESIUM ALGINATE; METOCLOPRAMIDE; MOTILIN; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; POTASSIUM BICARBONATE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SEROTONIN RECEPTOR; SIMPLYTHICK; SODIUM; THICKENING AGENT; UNCLASSIFIED DRUG; XANTHAN; DOPAMINE RECEPTOR BLOCKING AGENT;

AGITATION; APNEA; BONE MARROW SUPPRESSION; BRADYCARDIA; CARDIOTOXICITY; CLOSTRIDIUM DIFFICILE INFECTION; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSTONIA; ESOPHAGITIS; EXTRAPYRAMIDAL SYMPTOM; GASTROESOPHAGEAL REFLUX; HEART ARRHYTHMIA; HUMAN; HYPERNATREMIA; HYPERTROPHIC PYLORUS STENOSIS; INFECTIOUS DIARRHEA; INTESTINE MOTILITY; IRRITABILITY; LONG QT SYNDROME; LOWER RESPIRATORY TRACT INFECTION; META ANALYSIS (TOPIC); NAUSEA; NECROTIZING ENTEROCOLITIS; NEUROTOXICITY; NEWBORN DISEASE; NEWBORN INTENSIVE CARE; OSTEOPENIA; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SEPSIS; SIDE EFFECT; STOMACH PH; SYSTEMATIC REVIEW (TOPIC); TARDIVE DYSKINESIA; UNITED STATES; VENTILATOR ASSOCIATED PNEUMONIA; VISCOSITY; VOMITING; NEWBORN;

DOPAMINE ANTAGONISTS; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; METOCLOPRAMIDE; PROTON PUMP INHIBITORS;

EID: 84857097114     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2011.12.015     Document Type: Review

References (69)

1. Clark R.H., Bloom B.T., Spitzer A.R., et al. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006, 117(6):1979-1987.
2. Nelson S.P., Chen E.H., Syniar G.M., et al. Prevalence of symptoms of gastroesophageal reflux during infancy: a pediatric practice-based survey. Arch Pediatr Adolesc Med 1997, 151:569-572.
3. Martin A.J., Pratt N., Kennedy J.D., et al. Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics 2002, 109:1061-1067.
4. Malcolm W.F., Gantz M., Martin R.J., et al. National Institute of Child Health and Human Development Neonatal Research Network. Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants. Pediatrics 2008, 121(1):22-27.
5. Peter C.S., Sprodowski N., Bohnhorst B., et al. Gastroesophageal reflux and apnea of prematurity: no temporal relationship. Pediatrics 2002, 109:8-11.
6. Barrington K.J., Tan K., Rich W. Apnea at discharge and gastro-esophageal reflux in the preterm infant. J Perinatol 2002, 22:8-11.
7. Molloy E.J., Di Fiore J.M., Martin R.J. Does gastroesophageal reflux cause apnea in preterm infants?. Biol Neonate 2005, 87:254-261.
8. Kimball A.L., Carlton D.P. Gastroesophageal reflux medications in the treatment of apnea in premature infants. J Pediatr 2001, 138:355-360.
9. Di Fiore J., Arko M., Herynk B., et al. Characterization of cardiorespiratory events following gastroesophageal reflux in preterm infants. J Perinatol 2010, 10:683-687.
10. Snel A., Barnett C.P., Cresp T.L., et al. Behavior and gastroesophageal reflux in the premature neonate. J Pediatr Gastroenterol Nutr 2000, 30:18-21.
11. Rudolph C.D., Mazur L.J., Liptak G.S., et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001, 32(Suppl 2):S1-S31.
12. Horvath A., Dziechciarz P., Szajewska H. The effect of thickened-feed interventions on gastroesophageal reflux in infants: systematic review and meta-analysis of randomized, controlled trials. Pediatrics 2008, 122(6):e1268-e1277.
13. Craig W.R., Hanlon-Dearman A., Sinclair C., et al. Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database Syst Rev 2004, 4. CD003502.
14. Wenzl T.G., Schneider S., Scheele F., et al. Effects of thickened feeding on gastroesophageal reflux in infants: a placebo-controlled crossover study using intraluminal impedance. Pediatrics 2003, 111(4 Pt 1):e355-e359.
15. Corvaglia L., Ferlini M., Rotatori R., et al. Starch thickening of human milk is ineffective in reducing the gastroesophageal reflux in preterm infants: a crossover study using intraluminal impedance. J Pediatr 2006, 148(2):265-268.
16. Miller S. Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Curr Med Res Opin 1999, 15(3):160-168.
17. Corvaglia L., Aceti A., Mariani E., et al. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants. Aliment Pharmacol Ther 2011, 33(4):466-470.
18. Henney J.E. Withdrawal of troglitazone and cisapride. JAMA 2000, 283:2228.
19. Dubin A., Kikkert M., Mirmiran M., et al. Cisapride associated with QTc prolongation in very low birth weight preterm infants. Pediatrics 2001, 107(6):1313-1316.
20. Du W., Warrier I., Tutag Lehr V., et al. Changing patterns of drug utilization in a neonatal intensive care population. Am J Perinatol 2006, 23(5):279-285.
21. Kearns G.L., van den Anker J.N., Reed M.D., et al. Pharmacokinetics of metoclopramide in neonates. J Clin Pharmacol 1998, 38(2):122-128.
22. Hyman P.E., Abrams C., Dubois A. Effect of metoclopramide and bethanechol on gastric emptying in infants. Pediatr Res 1985, 19:1029-1032.
23. Hyman P.E., Abrams C.E., Dubois A. Gastric emptying in infants: response to metoclopramide depends on the underlying condition. J Pediatr Gastroenterol Nutr 1988, 7:181-184.
24. Kearns G.L., Butler H.L., Lane J.K., et al. Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1988, 7:823-829.
25. Harlev D., Mimouni F., Dollberg S. A clinical pilot trial of metoclopramide therapy for gastric residuals in preterm infants. Acta Paediatr 2007, 96(8):1239-1241.
26. Hibbs A.M., Lorch S.A. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics 2006, 118(2):746-752.
27. Craig W.R., Hanlon-Dearman A., Sinclair C., et al. Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database Syst Rev 2010, 5. CD003502.
28. Hyams J.S., Leichtner A.M., Zamett L.O., et al. Effect of metoclopramide on prolonged intraesophageal pH testing in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1986, 5:716-720.
29. Leung A.K., Lai P.C. Use of metoclopramide for the treatment of gastroesophageal reflux in infants and children. Curr Ther Res Clin Exp 1984, 36:911-915.
30. Machida H.M., Forbes D.A., Gall D.G., et al. Metoclopramide in gastroesophageal reflux of infancy. J Pediatr 1988, 112:483-487.
31. Shaffer D., Butterfield M., Pamer C., et al. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc (Wash DC) 2004, 44:661-665.
32. Mejia N.I., Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord 2005, 20:86-89.
33. Madani S., Tolia V. Gynecomastia with metoclopramide use in pediatric patients. J Clin Gastroenterol 1997, 24:79-81.
34. Ng P.C., So K.W., Fung K.S., et al. Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants. Arch Dis Child Fetal Neonatal Ed 2001, 84(3):F177-F182.
35. Ng E., Shah V.S. Erythromycin for the prevention and treatment of feeding intolerance in preterm infants. Cochrane Database Syst Rev 2008, 3. CD001815.
36. Ng S.C., Gomez J.M., Rajadurai V.S., et al. Establishing enteral feeding in preterm infants with feeding intolerance: a randomized controlled study of low-dose erythromycin. J Pediatr Gastroenterol Nutr 2003, 37(5):554-558.
37. Shoji H., Suganuma H., Daigo M., et al. Hypertrophic pyloric stenosis in mono-ovular extremely preterm twins after use of erythromycin. Pediatr Int 2008, 50(5):701-702.
38. Mahon B.E., Rosenman M.B., Kleiman M.B. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 2001, 139(3):380-384.
39. Ray W.A., Murray K.T., Meredith S., et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004, 351:1089-1096.
40. Bines J., Quinlan J.E., Treves S., et al. Efficacy of domperidone in infants and children with gastro-oesophageal reflux. J Pediatr Gastroenterol Nutr 1992, 14:400-405.
41. De Loore I., Van Ravenstein, Ameryckx L. Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation: a comparison with metoclopramide. Postgrad Med J 1979, 55:40-42.
42. Grill B.B., Hillemeier C., Semeraro L.A., et al. Effects of domperidone therapy on symptoms and upper gastrointestinal motility in infants with gastroesophageal reflux. J Pediatr 1985, 106(2):311-316.
43. Pritchard D.S., Baber N., Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol 2005, 59(6):725-729.
44. Franckx J., Noel P. Acute extrapyramidal dysfunction after domperidone administration. Helv Paediatr Acta 1984, 39:285-288.
45. Slocum C., Arko M., Di Fiore J., et al. Apnea, bradycardia and desaturation in preterm infants before and after feeding. J Perinatol 2009, 29(3):209-212.
46. Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol 2001, 15(3):511-521.
47. Cothran D.S., Borowitz S.M., Sutphen J.L., et al. Alteration of normal gastric flora in neonates receiving ranitidine. J Perinatol 1997, 17(5):383-388.
48. Guillet R., Stoll B.J., Cotten C.M., et al. National Institute of Child Health and Human Development Neonatal Research Network. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006, 117(2):e137-e142.
49. Bianconi S., Gudavalli M., Sutija V.G., et al. Ranitidine and late-onset sepsis in the neonatal intensive care unit. J Perinat Med 2007, 35(2):147-150.
50. Messori A., Trippoli S., Vaiani M., et al. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomized controlled trials. BMJ 2000, 321:1103.
51. Mehall J.R. Prospective study of the incidence and complications of bacterial contamination of enteral feeding in neonates. J Pediatr Surg 2002, 37(8):1177-1182.
52. Levy J. Enteral nutrition: an increasingly recognized cause of nosocomial bloodstream infection. Infect Control Hosp Epidemiol 1989, 10:395-397.
53. Yang Y.X., Lewis J.D., Epstein S., et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947-2953.
54. Gray S.L., LaCroix A.Z., Larson J., et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010, 170:765-771.
55. Kaye J.A., Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008, 28:951-959.
56. Cucchiara S., Staiano A., Romaniello G., et al. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child 1984, 59(9):842-847.
57. Orenstein S.R., Shalaby T.M., Devandry S.N., et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther 2003, 17(9):1097-1107.
58. Wheatley E., Kennedy K.A. Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants. J Pediatr 2009, 155(4):516-521.
59. Nault M.A., Milne B., Parlow J.L. Effects of the selective H1 and H2 histamine receptor antagonists loratadine and ranitidine on autonomic control of the heart. Anesthesiology 2002, 96:336-341.
60. 2-blocker modulates heart rate variability. Heart Vessels 1999, 14:137-142.
61. Amos R.J., Kirk B., Amess J.A., et al. Bone marrow hypoplasia during intensive care: bone marrow culture studies implicating ranitidine in the suppression of haemopoiesis. Hum Toxicol 1987, 6(6):503-506.
62. Barron J.J., Tan H., Spalding J., et al. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr 2007, 45(4):421-427.
63. Cucchiara S., Minella R., Iervolino C., et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993, 69(6):655-659.
64. Omari T.I., Haslam R.R., Lundborg P., et al. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr 2007, 44(1):41-44.
65. Moore D.J., Tao B.S., Lines D.R., et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003, 143(2):219-223.
66. Khoshoo V., Dhume P. Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 2008, 46(3):352-354.
67. van der Pol R.J., Smits M.J., van Wijk M.P., et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics 2011, 127(5):925-935.
68. Orenstein S.R., Hassall E., Furmaga-Jablonska W., et al. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009, 154(4):514-520.
69. Turco R., Martinelli M., Miele E., et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther 2010, 31(7):754-759.